At the 61st ASH Annual Meeting & Exposition, Editor-in-Chief of Oncology & Hematology Review (US) Shaji Kumar (Mayo Clinic) discusses the latest advances in the treatment and guidelines of multiple myeloma.
Questions
1. What have been the most exciting recent development in the treatment of multiple myeloma? (0:05)
2. According to the most recent guidelines, what criteria are used to assess eligibility for autologous stem-cell transplant (ASCT)? (1:52)
3. What are the options for first-line therapy in transplant-ineligible patients? (3:38)
4. What factors influence the choice of first relapse therapy? (5:30)
5. How does risk status influence therapy in myeloma (newly diagnosed and relapse)? (6:36)
Shaji Kumar has no conflicts of interest to declare in relation to this video.
Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.
